Skip to main content
 

This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.

Accept

Home

 

We are passionate about applying cutting-edge science
to the development of life-changing therapies. Cancer has no borders. Neither do we.

Our Story Pipeline

 
  • BeiGene Facts
  • Founded 2010
  • Listings NASDAQ: BGNE   HKEX: 06160
  • Internally Developed
    Clinical Candidates 6
  • Marketed Products
    in China 3
  • Global Team 2200+
About
 

About Us

A Business
Approach that Looks Beyond Borders

We are becoming a global leader in the discovery, development and commercialization of innovative, molecularly targeted and immuno-oncology drugs for the treatment of cancer.

About Us

Science
 

Our Expertise

Cancer is Relentless Our Scientists Are Too

We have developed broad internal capabilities utilizing rational drug design to identify and target the genes and proteins that drive cancer, as well as a unique immuno-oncology platform. Our R&D team is also exploring synergies between targeted and immuno-oncology combination therapies.

Pipeline

News

BeiGene News

  • March 6, 2019
    Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics

    Ambrx and BeiGene Announce Global Research and Development Collaboration to Develop Next-Generation Biologics

  • March 4, 2019
    BeiGene to Present at Upcoming Investor Conferences

    BeiGene to Present at Upcoming Investor Conferences

  • February 27, 2019
    BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results

    BeiGene Reports Fourth Quarter and Full Year 2018 Financial Results

  • February 22, 2019
    BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference

    BeiGene to Present at the 8th SVB Leerink Global Healthcare Conference

  • February 19, 2019
    BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma

    BeiGene Initiates Global Phase 2 Trial of Zanubrutinib in Patients with Relapsed or Refractory Marginal Zone Lymphoma

  • February 13, 2019
    BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong

    BeiGene to Hold Fourth Quarter and Full Year 2018 Financial Results Conference Call on February 27, 2019 and Host Investor Event in Hong Kong

story
 
  • 2010

    • BeiGene starts as a research and development company
    BeiGene Co-Founders, John V. Oyler and Xiaodong Wang, Ph.D.
  • 2012

    • Began work on both a PD-1 antibody and a BTK inhibitor
    Immuno-oncology Therapies
  • 2014

    • Started clinical trials of pamiparib and zanubrutinib
    Clinical Researcher
  • 2016

    • Went public on the Nasdaq, with $182 million initial public offering
    First China biotech to go public on the Nasdaq
  • 2018

    • 50+ ongoing or planned clinical trials
    BeiGene expands global operations

Our Story

Breaking Boundaries From the Beginning

From our start in Beijing with a handful of scientists and developers, to today, with a global team, a rich pipeline, strong partnerships, and commercial products. We have accomplished so much in a short time, and yet there is so much still to do.

Our Story

Partnering

Partnering

Partnerships that ExtendAround the Globe

BeiGene is the partner of choice in China for development and commercialization. Read more about our current partnerships and opportunities to build business relationships

Celgene LogoMirati LogoMei PharmaZymeworks

Partners

Patients
 

Our Patients

Our Commitment to
Patients

At BeiGene we are focused not only on the underserved global cancer patient population, but also on individual people fighting their illnesses.

Patients

Careers
 

Careers

Join Our
Team

We’re looking for highly motivated colleagues who can collaborate with us as we build a company that will have a lasting impact on the global fight against cancer.

Careers